SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

4 candidates mapped to SDH-deficient disease pathways

All (50)established (7)clinical trial (8)preclinical (13)theoretical (22)
Sunitinib

Sutent

established

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt
GISTPPGL/PCCRCC
Evidence Score
78
FDA Approved1 trial
Bevacizumab

Avastin

established

Anti-VEGF monoclonal antibody

Vegf SignalingHif Pseudohypoxia
PPGL/PCC
Evidence Score
67
FDA Approved
Cabozantinib

Cabometyx, Cometriq

established

Multi-kinase inhibitor (VEGFR2/MET/AXL/RET/KIT)

Hif Met Axl SignalingVegf Signaling
PPGL/PCCRCC
Evidence Score
62
FDA Approved3 trials
Regorafenib

Stivarga

established

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k AktFgfr Signaling
GISTRCC
Evidence Score
60
FDA Approved1 trial